Results 271 to 280 of about 25,658,089 (295)
Some of the next articles are maybe not open access.

A Patent Review of Topoisomerase I Inhibitors (2016–Present)

Expert Opinion on Therapeutic Patents, 2021
Francisco Palacios   +2 more
exaly  

Mutagenic activity of topoisomerase I inhibitors

Clinical cancer research : an official journal of the American Association for Cancer Research
Topoisomerase I-directed agents are now in Phase I and II clinical trials and show great promise as potentially important agents for cancer chemotherapy. Because of their mechanism of action they may also be potential mutagens; however, their mutagenicity and oncogenicity still remain to be elucidated.
, Hashimoto, , Chatterjee, , Berger
openaire   +1 more source

The clinical pharmacology of topoisomerase I inhibitors.

Seminars in hematology, 1999
The Chinese tree Camptotheca acuminata, or Xi Shu, brings us a unique class of chemotherapeutic agents known as the camptothecins. Because the parent compound exhibited excessive toxicity and poor aqueous solubility, synthetic and semisynthetic analogs were developed.
openaire   +1 more source

Catalytic Topoisomerase II Inhibitors in Cancer Therapy

Pharmacology & Therapeutics, 2003
Alexandre Escargueil   +2 more
exaly  

COVALENT CONJUGATES OF TOPOISOMERASE I AND TOPOISOMERASE II INHIBITORS

1999
LEE KUO-HSIUNG   +4 more
openaire   +3 more sources

Home - About - Disclaimer - Privacy